KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Asset Writedowns and Impairment: 2010-2024

Historic Asset Writedowns and Impairment for Nektar Therapeutics (NKTR) over the last 6 years, with Dec 2024 value amounting to $8.3 million.

  • Nektar Therapeutics' Asset Writedowns and Impairment fell 37.16% to $8.3 million in Q2 2024 from the same period last year, while for Jun 2024 it was $30.9 million, marking a year-over-year decrease of 11.59%. This contributed to the annual value of $8.3 million for FY2024, which is 76.42% down from last year.
  • Nektar Therapeutics' Asset Writedowns and Impairment amounted to $8.3 million in FY2024, which was down 76.42% from $35.3 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Asset Writedowns and Impairment registered a high of $65.8 million during FY2022, and its lowest value of $8.3 million during FY2024.
  • In the last 3 years, Nektar Therapeutics' Asset Writedowns and Impairment had a median value of $35.3 million in 2023 and averaged $36.5 million.
  • Data for Nektar Therapeutics' Asset Writedowns and Impairment shows a maximum YoY plummeted of 76.42% (in 2024) over the last 5 years.
  • Nektar Therapeutics' Asset Writedowns and Impairment (Yearly) stood at $65.8 million in 2022, then plummeted by 46.28% to $35.3 million in 2023, then crashed by 76.42% to $8.3 million in 2024.